Micelle

Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies : Industry Trends and Global Forecasts, 2022-2035

Retrieved on: 
Thursday, December 1, 2022
API, NCE, Permeability, Freeze-drying, Lipid, ADME, Microfluidics, Geography, Services marketing, Classification, Overalls, CPC, Solubility, Liposome, BCS, Chapter, Powder, Drug development, Patent, Nanotechnology, Liquid, Particulates, Absorption, Research, Therapy, Polymer, II, IV, Excipient, Benchmarking, Micelle, Metabolism, Pharmaceutical industry, Retail, Medical device, Extrusion, Generic drug, New chemical entity, USD, Solid

View original content:https://www.prnewswire.com/news-releases/bioavailability-enhancement-tec...

Key Points: 
  • Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates.
  • The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services.
  • A general introduction to bioavailability enhancement, featuring information on the historical overview of bioavailability, assessment of drug bioavailability, need for bioavailability enhancement, and general factors affecting drug bioavailability.
  • Additionally, the chapter includes details on the various types of bioavailability enhancement approaches / technologies employed by various industry stakeholders.

Nanopesticide Market Report 2022: Boosts for Vegetative Growth, Reproductive Development, and Blooming Driving Adoption - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
Agriculture, Natural Resources, Marketing, Nanoparticle, Carbon, Micelle, Utility, Ginkgo Bioworks, Zeolite, Chitin, Nanostructure, Pest control, Chitosan, Porter's five forces analysis, Benchmarking, Renewable energy, Agriculture, Retail, Bayer, Corteva

Nanopesticides can boost vegetative growth, reproductive development, and blooming, thus increasing output, fruit quality, and shelf-life.

Key Points: 
  • Nanopesticides can boost vegetative growth, reproductive development, and blooming, thus increasing output, fruit quality, and shelf-life.
  • The report features the strategies adopted by key market players to maintain their foothold in the market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the nanopesticide market analysis from 2021 to 2031 to identify the prevailing nanopesticide market opportunities.
  • The report includes the analysis of the regional as well as global nanopesticide market trends, key players, market segments, application areas, and market growth strategies.

Albolene Introduces New Line of Hydrating Facial Cleansers, Providing Skincare Fans with the Ultimate #FoundationForBoldness

Retrieved on: 
Wednesday, August 17, 2022
Irritation, Shea, Trial of the century, Dry, Technology, Hydration, Hyaluronic acid, Micelle, Skin, Vitamin C, MSRP, Dermatology, Amazon, Elasticity, Cosmetics

CHATTANOOGA, Tenn., Aug. 17, 2022 /PRNewswire/ -- Albolene, the legacy skincare brand and consumer staple across generations, today announced the launch of its new line of hydration-packed facial cleansers. Designed to leave skin soft and nourished, without irritation or dryness, the new products include: a Hydrating Cleansing Balm, a Hydrating Daily Cleanser and a Hydrating Micellar Milk Cleanser.

Key Points: 
  • CHATTANOOGA, Tenn., Aug. 17, 2022 /PRNewswire/ -- Albolene , the legacy skincare brand and consumer staple across generations, today announced the launch of its new line of hydration-packed facial cleansers.
  • Designed to leave skin soft and nourished, without irritation or dryness, the new products include: a Hydrating Cleansing Balm, a Hydrating Daily Cleanser and a Hydrating Micellar Milk Cleanser.
  • For over a century, Albolene has delivered proven effectiveness in gently cleansing and moisturizing skin, serving as a skincare staple from bathroom medicine cabinets to professional stage makeup kits.
  • Founded in 1885, Albolene is a classic skincare brand and favorite across generations.

Micellae Delivery Systems Appoints Dr. Andrew Kerklaan as CEO

Retrieved on: 
Wednesday, August 10, 2022
Multimedia, Drink, Industry, CEO, Technology, Growth, Board, Patent, Toronto, Marketing, Cannabinoid, Therapy, Company, Solubility, Capsule, PEG, Tablet, University, University of Toronto, Management, Pharmaceutical industry, Medical device, Micelle

TORONTO, Aug. 10, 2022 /PRNewswire/ - Micellae Delivery Systems Inc. ("Micellae"), the provider of best-in-classsolubility and bioavailability-enhancing technology for cannabinoids, is pleased to announce the appointment of Dr. Andrew Kerklaan as the Company's new Chief Executive Officer.

Key Points: 
  • TORONTO, Aug. 10, 2022 /PRNewswire/ - Micellae Delivery Systems Inc. ("Micellae"), the provider of best-in-classsolubility and bioavailability-enhancing technology for cannabinoids, is pleased to announce the appointment of Dr. Andrew Kerklaan as the Company's new Chief Executive Officer.
  • "Andrew has an impressive track record; we are delighted to welcome him to the team," Dr. Nouraei added.
  • Dr. Kerklaan is a pioneer in the cannabis sector, who has brought to market many health-focused cannabinoid products.
  • About Micellae Delivery Systems Inc.
    Micellae is the provider of best-in-classsolubility and bioavailability-enhancing technologies for cannabinoids and other cannabis-derived compounds.

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Retrieved on: 
Wednesday, May 18, 2022
DCI, Death, Telephone, Postherpetic neuralgia, A-T, U.S. Securities and Exchange Commission, AES, SAH, Incidence, Skull, Patient, PHN, NASDAQ, Nimodipine, ASAH, Nerve Damage, SubArachnoid Space, IV, Stroke, Brain, COVID-19, Bleeding, Marketing, Capsule, FDA, Meal, Aneurysm, Plasma, Securities Exchange Act of 1934, Micelle, Subarachnoid hemorrhage, Securities Act of 1933, Neuropathic pain, Disability, Compliance, Rupture, Risk, Drug Quality and Security Act, NDA, Somnolence, Private Securities Litigation Reform Act, Headache, Security (finance), Blood, GI, Vaccine, Online shopping, Medical imaging, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints. The primary objective of the study was to evaluate the relative bioavailability of IV GTX-104 compared to oral nimodipine in healthy adult male and female subjects, while the secondary objective was to assess its safety and tolerability. The Company plans to submit these results to the US Food and Drug Administration (FDA), along with its proposed study design for the Phase 3 safety study which is on track to start in the second half of 2022. The safety study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting a New Drug Application to the FDA.

Key Points: 
  • In addition, the diurnal variation associated with IV GTX-104 was approximately half of that seen with the oral nimodipine capsules.
  • Diurnal variation takes into consideration variation in body functions (blood flow, renal function and hepatic metabolism) over the course of a day.
  • Acasti will host a conference call on Wednesday, May 18, 2022 at 1:00 PM Eastern Time to discuss the results of the trial.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Worldwide Micellar Water Industry to 2027 - Players Include Glossier, Garnier and Maybelline Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 13, 2022
Other Natural Resources, Natural Resources, Growth, Micelle, Skin, Soap, Detergent

The "Global Micellar Water Market to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Micellar Water Market to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Micellar water is a skincare product which is mainly used to remove makeup, and skin cleaning.
  • Rise in demand for micellar water in cosmetic industry is expected to boost the global micellar water market growth.
  • However, product recall is the major restraining factor for market which is expected to hamper the growth of global micellar water market.

IACTA Pharmaceuticals and TALLC Corporation Announce Strategic Collaboration to Utilize Novel SmartCelle Topical Delivery Technology

Retrieved on: 
Wednesday, December 15, 2021
Biotechnology, Pharmaceutical, Optical, Health, Glaucoma, Company, Private Securities Litigation Reform Act, Duane syndrome, Macular degeneration, Insufflation, Cornea, Dry eye syndrome, Micelle, Patient, Therapy, SmartCell Technology, SYK, CB2, Program, Partnership, Ophthalmology, Pharmaceutical industry, TALLC, Inc., IACTA Pharmaceuticals, Inc., TALLC, INC., IACTA PHARMACEUTICALS, INC.

The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.

Key Points: 
  • The agreement grants IACTA the use of TALLCs proprietary SmartCelle micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development.
  • IACTA plans to utilize TALLCs SmartCelle technology to deliver one or more of its novel ophthalmic therapeutics, as well as co-develop new ophthalmology therapeutic candidates that leverage IACTAs formulation and clinical expertise with TALLCs novel delivery technology.
  • TALLCs proprietary SmartCelle pan-ocular drug delivery technology employs 30nm micelles that enable delivery of difficult to formulate drugs into corneal and retinal tissues after topical delivery.
  • IACTA is a registered trademark of Iacta Pharmaceuticals, Inc. SmartCelle is a trademark of Altus Formulation licensed to TALLC Inc. All other trademarks are owned by their respective owners.

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Retrieved on: 
Thursday, December 2, 2021
American Heart Association, Nimodipine, Group B, DCI, Blood, Death, Company, Compliance, Rupture, TSX, Brain, New Drug Application, Physician, Disability, GLOBE, Incidence, Marketing, NDA, ASAH, Skull, Nerve Damage, Stroke, Securities Exchange Act of 1934, Blood pressure, PK, Private Securities Litigation Reform Act, Vasospasm, Bleeding, Cmax, Group A, Water, ACST, Trial of the century, Review, SAH, IV, Vital signs, Postherpetic neuralgia, Hypotension, Neuropathic pain, FDA, Headache, Association, Standard of care, Securities Act of 1933, Patient, A-T, Safety, Drug Quality and Security Act, Risk, Acquisition, Capsule, Aneurysm, SubArachnoid Space, PHN, SEC, COVID-19, CRU, Micelle, AUC, NASDAQ, Medical imaging, Pharmaceutical industry

As observed in a previous PK study, the inter- and intra-subject variability in the interim analysis was much lower for GTX-104 as compared with oral nimodipine.

Key Points: 
  • As observed in a previous PK study, the inter- and intra-subject variability in the interim analysis was much lower for GTX-104 as compared with oral nimodipine.
  • "This interim data is very encouraging, as it suggests that our current infusion protocol is on track to meet the objectives for this pivotal PK study.
  • In just three months since completing the acquisition, we launched this pivotal PK bridging study for GTX-104 and already have positive interim data with more data to follow in the first half of 2022.
  • The PK bridging study for GTX-104 is being conducted in a total of 50 healthy subjects as a single center, randomized, two-period crossover study.

Eclipse Foods Brings Plant-Based Ice Cream To Whole Foods Market

Retrieved on: 
Monday, November 22, 2021
Cream, Dark, Magic, CEO, Ice cream, Cookie butter, Gopuff, Whole Foods Market, Taste, Foxtrot, Gelson, The Good Food Institute, SAN, Plant, Amazon Fresh, Good Food, Central Market, Instagram, Micelle, LinkedIn, Nut, Vanilla ice cream, Growth, Grocery store, Dairy product

When a blind taste test of Eclipse ice cream and dairy ice cream was conducted, 73% of participants said Eclipse is creamier than the bestselling dairy ice cream.

Key Points: 
  • When a blind taste test of Eclipse ice cream and dairy ice cream was conducted, 73% of participants said Eclipse is creamier than the bestselling dairy ice cream.
  • "Entering Whole Foods Market, a retailer synonymous for offering premium ingredient, high-caliber products, marks an important moment for Eclipse as we continue to grow our retail presence nationwide," said Aylon Steinhart, co-founder and CEO, Eclipse Foods.
  • Eclipse is available via direct-to-consumer at www.eclipsefoods.com and in retailers nationwide including Amazon Fresh, Central Market, Gelson's, Foxtrot, New Seasons, Roots Market and select Whole Foods Market locations, among other regional retailers.
  • Eclipse is also available for purchase on grocery delivery platform GoPuff in select regions, as well as all 28 Afters Ice Cream locations among other foodservice partners.

DGAP-News: Solv4U: Marinomed launches new business area enabling the development of innovative formulations in technology partnerships

Retrieved on: 
Wednesday, November 3, 2021
Online, Degenerative disease, Infection, Peptide, Technology, Solubility, Drug development, Wiener Börse, Exhibition, VSE, Drug discovery, Severe acute respiratory syndrome coronavirus 2, Hotel manager, ICSE, Mark (given name), Risk, Conference, API, Nasal spray, Therapy, Micelle, Pharmaceutical industry, Fine chemical, Animal, Marinosolv, Marinomed Biotech AG, MARINOSOLV, MARINOMED BIOTECH AG

"We are excited that with our new business area, Solv4U, the advantages of Marinosolv are now available for pharma- and biotech customers through technology partnerships.

Key Points: 
  • "We are excited that with our new business area, Solv4U, the advantages of Marinosolv are now available for pharma- and biotech customers through technology partnerships.
  • High bioavailability is a key requirement in drug development and with Solv4U partnerships, we can provide a clinically validated solution," said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer of Marinomed.
  • Solv4U partnerships address this inherent challenge in drug development and rely on a clinically proven technology.
  • Under the brand Solv4U, Marinomed provides Marinosolv(R) formulation development in technology partnerships for active ingredients at all stages of drug discovery and lifecycle extension.